Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 9/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899970 | 0.81 | LMNA (0.35) | LMNAMAPTNPSR1HTTSPR | |
| SCHEMBL1817756 | 0.80 | KMT2A (0.40) | LMNAMAPTNPSR1HTTSPR | |
| SCHEMBL15799985 | 0.75 | RAB9A (0.34) | LMNAMAPTNPSR1HTTKMT2A | |
| SCHEMBL5238342 | 0.72 | MAPK1 (0.41) | LMNAKMT2A | |
| SCHEMBL6899995 | 0.67 | LMNA (0.37) | LMNAMAPTSPRKMT2AALDH1A1 | |
| SCHEMBL432793 | 0.66 | LMNA (0.45) | LMNAMAPTNPSR1HTTSPR | |
| SCHEMBL15373204 | 0.66 | MAPK1 (0.52) | MAPTNPSR1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL5529616 | 0.66 | LPL (0.34) | KMT2A | |
| SCHEMBL432792 | 0.65 | KMT2A (0.52) | LMNAMAPTNPSR1HTTSPR | |
| SCHEMBL2274567 | 0.64 | LPL (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258299-B2 | Process for preparation of temsirolimus | Chungwa Chemical Synthesis & Biotech Co., Ltd. (TW) | 2012-09-04 | — | — | US | disclosed |
| US-8258299-B2 | Process for preparation of temsirolimus | Chungwa Chemical Synthesis & Biotech Co., Ltd. (TW) | 2012-09-04 | — | — | US | disclosed |
| US-20100249415-A1 | Process for preparation of temsirolimus | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2010-09-30 | — | — | US | disclosed |
| US-20100249415-A1 | Process for preparation of temsirolimus | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. (TW) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249415-A1 | Process for preparation of temsirolimus | RICTOR, MTOR, MLST8 | LMNA 3396/4885MAPT 2047/4885NPSR1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.